

2024 ANNUAL REPORT



Protecting people
from global diseases
since 2000

Foreword From DCVMN's Board Chair

Dear DCVMN members and colleagues,

On behalf of DCVMN Board, I am happy to present to you the DCVMN Annual Report for 2024.

The 25th General Assembly held in São Paulo, Brazil, in 2024 coincided with the silver jubilee of DCVMN, marking 25 years of its existence. We have gone through a long journey to become what we are today.

Our network has grown stronger, embracing new technologies, enhancing regulatory pathways and fostering over 40 new partnerships including around 15 south-south collaborations that accelerate equitable vaccine distribution. Together, we have demonstrated that locally produced vaccines are not just a solution but a necessity in safeguarding global health. We have been instrumental in providing 60% of the global Covid-19 vaccines production during the COVID-19 pandemic. This goes to show the strategic role of DCVMN members in supporting global health through the provision of the much-needed vaccines. Through our collective efforts, we have strengthened global access to life-saving vaccines, driving innovation and expanding capacity to address emerging health challenges.

As we move forward, our commitment remains unwavering—to advance vaccine manufacturing capabilities, ensure accessibility, and uphold our mission of protecting lives across developing nations. I extend my deepest gratitude to each member, partner, and stakeholder who has contributed to this vision.

With optimism and determination, let us continue to shape a healthier future for all.

Warm regards,



Adriansjah Azhari

DCVMN Board Chair

Message From The CEO

Dear Members,

I am pleased to share with you that for the fiscal year 2024, DCVMN International has made substantial strides across five strategic initiatives under the DCVMN Training Upgradation Project. In 2025 we intend progressing and excelling on the following focused programs:

- 1. Successful launch of the 5th Technology Transfer Training (TTT5).*
- 2. Offering 4.5 times more of hands-on learning, Vis-a-vis the previous iteration.*
- 3. Concurrently, developing two strategic competency workshops, on Quality by Design (QbD) and Manufacturing Science Group (MSG), to advance technical self-reliance, particularly in Africa and LATAM.*
- 4. Organising a specialized Intellectual Property workshop in partnership with WIPO reflecting DCVMN's push for sustainable innovation and knowledge dissemination.*
- 5. Identified the Learning & Development (L&D) Working Group core training themes such as quality culture, leadership, and communication, while progress is being made on engaging a content development agency and VR-based module development on aseptic simulation and behaviour.*

DCVMN has demonstrated clear momentum in building a future-ready training ecosystem, leveraging member collaboration, strategic partnerships, and digital innovation. Through improved training delivery, enhanced content and specialized workshops, DCVMN is not only closing skill gaps but also empowering member manufacturers for long-term success.

The alignment with WHO standards in VR compatibility, clear emphasis on quadrupled hands-on experience during Tech Transfer Training and a methodical approach to business model sustainability underscore DCVMN's commitment to excellence and impact. The groundwork done so far has created a strong platform for scaling up training outreach and ensuring resilience in training operations through strategic diversification of funding models.

As the next phase begins, emphasis will remain on measurable outcomes, continued collaboration, and adaptive learning solutions tailored to the evolving needs of vaccine

manufacturers in LMICs in addition to continuing strong representation and advocacy of our member network in terms of Voice Share and Wallet Share!

Looking forward to your continued support to deliver desired influence and impact!



Rajinder Suri

CEO of DCVMN International

A background image showing rows of glass vials or test tubes in a laboratory setting, some containing liquids, arranged in a grid-like pattern.

Table of Contents

04

ABOUT DCVMN

09

OUR 2025 OBJECTIVES AND STRATEGIES

10

DCVMN & NEWS FROM MEMBERS

15

DCVMN TRAININGS FOR SUSTAINABLE VACCINE MANUFACTURING

20

EXPERT WORKING GROUPS

27

DCVMN REPRESENTATION AT GLOBAL MEETINGS

30

25TH ANNUAL GENERAL MEETING

32

FINANCIAL STATEMENTS

36


ANNEX

Who we are

The Developing Countries Vaccine Manufacturers Network International (DCVMN) is a global alliance of over 45 manufacturers from 17 LMICs, collectively supplying more than 60% of the vaccines procured globally and reaching over 170 countries worldwide.

Our mission is to strengthen the capacity of vaccine producers in the Global South through policy advocacy, technical training, and access to innovation. We support members in advancing R&D, obtaining funding, scaling up manufacturing, and meeting international quality standards to ensure timely, affordable, and equitable access to vaccines.

DCVMN serves as a platform for collaboration - connecting manufacturers with each other and global health partners, enabling technology transfers, strategic partnerships, and driving sustainable solutions to meet current and future public health needs.





VISION

To protect people of all age groups in low-middle income countries and emerging economies against dreaded infectious diseases by augmenting the capacity of vaccine manufacturers in developing countries, to innovate, develop, produce and deliver a consistent and sustainable supply of quality vaccines at affordable prices to accelerate and reach the goal of global vaccine equity!

MISSION

To foster a voluntary alliance of vaccine manufacturers from developing countries to develop collaborations and communication amongst them and with other industry associations and academia to leverage research, production and roll-out efforts to meet vaccine needs, strive for international recognition and attaining the status of WHO pre-qualification for a range of vaccines.

STRATEGIC OBJECTIVES



To augment the capacity of vaccine manufactures and potentially other health technology producers, in developing countries, to innovate, develop, produce and deliver quality vaccines and other health technologies effectively at affordable prices for introduction in the national immunization programs in a sustainable manner;



To encourage and support sustainable public-private partnerships, while also aiming for global governance strategies that focus on economic incentives for vaccine manufacturers, is essential. This ensures sustainability in the market and helps provide technical assistance to manufacturers in developing countries throughout all stages of vaccine production and distribution;



To promote the sharing of ideas and experiences between DCVMs and their counterparts in developed nations through innovative ownership models and intellectual property sharing related to health advancement. Encourage the involvement of vaccine and health technology manufacturers from developing countries in global strategic planning and decision-making processes;



To disseminate comprehensible information to the broader public health community and the general public to increase vaccine confidence;



To encourage compliance of members of the network with National Regulatory Authorities (NRA) and WHO requirements.

2024 HIGHLIGHTS



DCVMN AGM Silver Jubilee

In 2024, we proudly celebrated the 25th DCVMN Annual General Meeting, a remarkable evolution from a small manufacturers' gathering into a flagship event for vaccine producers, global health institutions, and international partners. To honor this milestone, we released a [short documentary](#) highlighting DCVMN's journey and growing role in advancing global vaccine equity.



Four New Working Groups

The year of 2024 marked a year of growth for DCVMN's working groups. Two groups established in 2023 hit the ground running, delivering strong results in their first year. Meanwhile, two new working groups were launched, laying the groundwork to begin impactful contributions in 2025, reinforcing our commitment to collective innovation and capacity building across the network.



Advocacy and Representation

In 2024, DCVMN's presence on the global stage continued to grow, with increased participation in key international conferences and forums. This expanding visibility is not only strengthening the voice of DCVMs, but also ensuring their perspectives are actively represented in global health dialogues.



Webinar Record Attendance

Our webinar on "Innovative Vaccine Technology Transfer and Local Manufacturing" set a new milestone in 2024, achieving the highest attendance in four years with 175 participants.

DCVMN IN NUMBERS



170

Countries supplied with vaccines manufactured by DCVMN members, covering many MICs, LMICs and LICs



>75%


of Gavi's vaccines supplied by DCVMN Member companies in 2024



400+

Vaccine products manufactured by DCVMN member companies, covering the most used and needed vaccines worldwide

Vaccines manufactured by most members




6+ billion

Doses manufactured each year



80+

Of the vaccines manufactured in the Network have WHO Prequalification



8

Different vaccine technology platforms are being used to develop COVID-19 vaccines between all of our 20 members that are engaging in the COVID-19 vaccine effort

DCVMN's Objectives and Strategies for 2025



1

Be the principal partner of International Organizations for pandemic preparedness and response of DCVMs.

2

Support regional vaccine manufacturing excellence and foster South-South collaborations.

3

Advocate for our Members' voice and wallet share.

4

Learning & Development to build work force capability and capacity by the creation of a professional development community of practice made up of training and professional development staff from member organizations.

5

Provide access to training technologies or licenses to members.

6

Convergence on regulatory framework & CRP.

News from Members and DCVMN

DCVMN JOINT STATEMENT ON BIOPHARMACEUTICAL INDUSTRY COMMITMENTS

Geneva, 14 Mar. 2024 - DCVMN joined a landmark joint statement led by IFPMA and global pharmaceutical trade associations to advance equitable access to essential medical countermeasures before and during pandemics. The statement introduces a new model of legally binding commitments aimed at fostering a transformative, multi-stakeholder partnership. Companies are encouraged to join this initiative by adopting the Equitable Access Commitments.

DCVMN AT THE INTERNATIONAL CONFERENCE ON INNOVATION, INTELLECTUAL PROPERTY, AND TECHNOLOGY TRANSFER IN AFRICA'S PHARMACEUTICAL SECTOR

Addis Ababa, 31 Mar. 2024 – DCVMN CEO participated as a panelist at the “International Conference on Innovation, Intellectual Property, and Technology Transfer in Africa’s Pharmaceutical Sector.” The event aimed to advance local pharmaceutical production and strengthen Africa’s preparedness for future health emergencies. Mr. Suri joined distinguished experts in a session titled “Private Sector Innovation in Africa: New Partnerships, New Horizons,” where discussions focused on leveraging past experiences, addressing production challenges, and fostering strategic partnerships.

DCVMN CHAIRED CONFERENCE IN BOTSWANA

Gaborone, 18 Mar. 2024 - DCVMN CEO chaired high-level conference in Botswana, focused on “Facilitating Technology Transfer to Promote Local Manufacturing and Access to Vaccines, Medicines, and Health Technologies in Sub-Saharan Africa.” Organized by WHO's Local Production & Assistance Unit in collaboration with Africa CDC and the European Union. Mr. Suri’s session emphasized the role of technology transfer and strategic partnerships in achieving national and continental manufacturing goals. Key presentations and panel discussions, featuring leaders from Afrigen, Biovac, Aspen, and the IFC, highlighted innovation opportunities and shared practical insights from ongoing projects.

DCVMN CEO ENGAGEMENTS IN ADDIS ABABA

Addis Ababa, 3 Apr. 2024 - As part of its ongoing global advocacy efforts, Mr. Suri visited Addis Ababa for high-level meetings with African Union Deputy Chairperson H.E. Dr. Monique Nsanzabaganwa and Ethiopia's Health Minister H.E. Mekdes Daba Feyssa. These engagements underscored DCVMN's commitment to representing the interests of DCVMs and strengthening partnerships to advance public health across Africa. The discussions focused on the vital role of DCVMs in supporting equitable access to vaccines and fostering innovation in global health.

DCVMN AT THE WORLD VACCINE CONGRESS BIODEFENCE PRE-WORKSHOP

Washington DC, 10 Apr. 2024 - DCVMN CEO participated in the World Vaccine Congress BioDefence Pre-Workshop contributing to a key panel on achieving the 100 Days Mission to rapidly detect and control health threats. The session explored the feasibility of the mission and the role of global collaboration. Mr. Suri provided a strong voice for its members, offering practical insights into the mission's feasibility from a manufacturing perspective. He outlined key operational realities for manufacturers in LMICs and candidly addressed current bottlenecks, such as supply chain vulnerabilities and limited surge capacity and proposed actionable solutions for overcoming these hurdles. He also stressed the importance of embedding equity in pandemic preparedness strategies, ensuring that vaccine producers from the Global South are fully integrated into global response frameworks.

DCVMN CEO INAUGURATING THE VACCINE WORLD FORUM

Pune, 25 Apr. 2024 – DCVMN CEO Mr. Suri had the honour of inaugurating the Vaccine World Forum joining prominent leaders from across the vaccine ecosystem. The forum explored key trends in vaccine development, manufacturing, regulation, and emerging technologies, offering global and local insights. The event fostered meaningful dialogue and collaboration among industry, science, and policy leaders, reinforcing collective efforts to advance global health and innovation.

DCVMN BOARD AT THE WORLD VACCINE CONGRESS

Washington DC, 11 Apr. 2024 - At the 24th Annual World Vaccine Congress, DCVMN made a strong impression, with key contributions from its Board Members during a panel on the role of DCVMs in global immunization and pandemic preparedness. Board Members emphasized the importance of equitable access to vaccines, especially for LMICs, and called for sustained collaboration among manufacturers. They highlighted lessons from COVID-19, the need for regional production and funding strategies, and praised the contributions of Bio-Manguinhos / Fiocruz, Instituto Butantan, and South Korean manufacturers. The Board reaffirmed DCVMN's role in uniting members to strengthen pandemic preparedness and global health impact.

DCVMN BOARD AT THE 8TH INTERNATIONAL SYMPOSIUM ON IMMUNOBIOLOGICALS

Rio de Janeiro, 8 May 2024 - The DCVMN Board convened at the 8th International Symposium on Immunobiologicals, hosted by Bio-Manguinhos / Fiocruz. The DCVMN Board and CEO led a dedicated session DCVMN's role in empowering manufacturers in developing countries through strategic partnerships, workforce development, funding opportunities, and global advocacy. The panel highlighted that sustainable vaccine manufacturing, not just rapid scale-up, is key to equitable access. They underlined the importance of long-term collaborations with multinational partners, to build resilient regional production capacity.

DCVMN CO-AUTHORS CALL FOR EQUITABLE PANDEMIC AGREEMENT

23 May 2024 - Mr. Suri, alongside key partners and members, co-authored a pivotal article titled "The Pandemic Agreement: A Bridge to Nowhere or North Star to Access and Global Health Security?" published by Health Policy Watch. The piece emphasizes the urgent need for a global pandemic accord that ensures equitable access to vaccines and health technologies, particularly for LMICs. It underscores the importance of international collaboration, technology transfer, and combating misinformation to strengthen global health security. The authors advocate for a pandemic agreement that is inclusive, transparent, and centered on equity.

DCVMN CEO ATTENDING PRIVATE SESSION AT THE PERMANENT MISSION OF FRANCE TO THE UN

Geneva, 2 June 2024 – Mr. Suri as a member of the RVMC Strategic Advisory Board, participated in a closed-door session titled "From Investment to Impact: Promoting the Financial Sustainability of Regionalized Manufacturing" during WHA77 in Geneva. Co-hosted by RVMC, MPP, WHO, and the Permanent Mission of France, the event gathered global health leaders to discuss innovative solutions for financing and sustaining regional vaccine production. DCVMN remains committed to supporting collaborative efforts that strengthen global health resilience.

DCVMN JOINT STATEMENT AT WHA77

Geneva, 29 May 2024 - DCVMN contributed to a joint statement delivered at the 77th World Health Assembly, underscoring the important role of collaboration between vaccine manufacturers and global health stakeholders. The statement reflects a united commitment to advancing a meaningful pandemic agreement that strengthens the global innovation ecosystem and ensures timely, equitable access to vaccines and health tools. Together with partners, DCVMN emphasized the importance of fostering an environment that empowers companies, especially in developing countries.

DCVMN AT THE "ADVANCING BIOMANUFACTURING WORKFORCE TRAINING FOR GLOBAL HEALTH EQUITY" ADVOCACY EVENT

Geneva, 2 June 2024 - During the WHA77 DCVMN CEO participated in the "Advancing Biomanufacturing Workforce Training for Global Health Equity" advocacy event as a panelist in a session focused on the need for coordinated, partnership-driven approaches to workforce development in LMICs. The event was hosted by Germany's Federal Ministry for Economic Cooperation and Development (BMZ), with support from WHO and Africa CDC, brought together global leaders in talent development to explore strategies for scaling biomanufacturing training and fostering stronger alignment across regions.

DCVMN AT THE GLOBAL FORUM FOR VACCINE SOVEREIGNTY AND INNOVATION

Paris, 25 June 2024 - DCVMN had the honour of attending the Global Forum for Vaccine Sovereignty and Innovation. Held in the presence of H.E. President Emmanuel Macron and several heads of state and ministers from African nations, the event marked the launch of the African Vaccine Manufacturing Accelerator (AVMA) and the Gavi 6.0 replenishment call. The Forum underscored global commitment to advancing vaccine equity and self-reliance, with notable announcements of new technology transfer deals. These included a five-valent meningitis vaccine partnership between DCVMN member EuBiologics and Biovac, and an HPV vaccine bulk transfer from Inovax to ATLANTIC Lifesciences.

DCVMN CONTRIBUTES TO GLOBAL DIALOGUE AT THE GLOBAL PANDEMIC PREPAREDNESS SUMMIT

Rio de Janeiro, 30 July 2024 – DCVMN played an active role at the Global Pandemic Preparedness Summit 2024, co-hosted by Brazil's Ministry of Health, Fiocruz, and CEPI. The event convened global leaders to discuss strategies for enhancing future pandemic readiness. DCVMN's leadership from the Board and CEO Rajinder Suri joined industry and public health stakeholders for two days of high-level discussions. During a key session on enabling equitable access through local and regional production, DCVMN highlighted five critical areas: strengthening local manufacturing, advancing workforce and R&D capacity, improving coordination of funding and initiatives, supporting trust-based technology transfer, and calling for sustainable, long-term investment strategies across the vaccine value chain.

DCVMN AT THE "2ND EDITION OF THE GLOBAL EVENT ON HARNESSING PRIVATE SECTOR ENGAGEMENT FOR SUSTAINABLE VACCINE AND PHARMACEUTICAL MANUFACTURING IN AFRICA"

Nairobi, 2 July 2024 - Rajinder Suri participated in the 2nd Global Event on Harnessing Private Sector Engagement for Sustainable Vaccine and Pharmaceutical Manufacturing in Africa, co-organized by the WHO, Africa CDC, and the European Commission. The event focused on strengthening private sector involvement to drive sustainable pharmaceutical manufacturing on the continent. Mr. Suri spoke during the plenary session on "Assessing Industry Development Support Programmes," where he highlighted DCVMN's role in advancing industry support initiatives and shared strategies to accelerate private sector engagement in meeting Africa's healthcare needs.

PANACEA BIOTEC AND ICMR LAUNCH PHASE III TRIALS OF INDIA'S TETRAVALENT DENGUE VACCINE CANDIDATE

New Delhi, 15 Aug. 2024 - DCVMN member Panacea Biotec, in collaboration with the Indian Council of Medical Research (ICMR), commenced Phase III clinical trials of its tetravalent dengue vaccine candidate, DengiALL, following approval from the Drugs Controller General of India. The trial will enroll 10,335 participants across 19 sites nationwide. The DengiALL development journey began in 2006 with the licensing and transfer of attenuated tetravalent dengue virus strains from the U.S. National Institutes of Health to Panacea. Phase I/II trials in the Indian population were successfully completed with three years of safety data. Marking a significant step toward dengue prevention in India.

EXPLORING KEY STRATEGIES FOR SCALING UP MCM MANUFACTURING AT THE I- MCM-NET PARTNERS MEETING

Geneva, 19 Sept. 2024 - DCVMN CEO participated in the i-MCM-Net Partners Meeting. The WHO-led initiative aims to strengthen global readiness and equitable access to medical countermeasures during public health emergencies. Mr. Suri contributed to a roundtable on scalable manufacturing, chaired by Dr. Jicui Dong, focusing on adaptable production platforms, geo-diversified manufacturing, ever-ready facilities, and stronger regulatory systems, especially for LMICs. He emphasized the vital role of developing country vaccine manufacturers in expanding equitable access and proposed deeper engagement with WHO, including a focused dialogue on Mpox.

GREENSIGNAL BIO PHARMA ACHIEVES WHO PREQUALIFICATION FOR BCG VACCINE

Chennai, 10 Dec. 2024 – DCVMN member GreenSignal Bio Pharma Pvt Ltd on receiving WHO Prequalification for its BCG vaccine. The BCG vaccine is essential in preventing tuberculosis, a major global health challenge. WHO Prequalification confirms the vaccine meets international standards of quality, safety, and efficacy, paving the way for broader access in LMICs. This achievement reinforces global supply resilience and reflects the critical contribution of DCVMN members in expanding equitable access to essential vaccines.

PRESENTING DCVMN'S STRATEGIC FOCUS FOR 2024- 25 AT THE 2024 UNICEF VACCINE INDUSTRY CONSULTATION

Copenhagen, 20 Sept. 2024 - At the 2024 UNICEF Vaccine Industry Consultation, Mr. Suri outlined DCVMN's strategic goals for 2024–2025, focusing on boosting self-reliance and regional health security in LMICs through sustainable local vaccine production. Key focus areas included accelerating R&D and manufacturing through innovation and partnerships, such as CEPI's 100 Days Mission, advancing regulatory harmonization, and supporting environmental sustainability through a new Net Zero pilot project. The panel also highlighted the role of Gavi's AVMA and First Response Fund in supporting African manufacturers, underscoring the need for early engagement, clear market forecasts, and upfront support to ensure lasting impact.

DCVMN Training Programmes

At DCVMN, strengthening the capabilities of vaccine manufacturers goes beyond technology, it starts with the workforce. To ensure our members remain agile, innovative, and aligned with global standards, we have developed a comprehensive portfolio of training initiatives designed to build a skilled and future-ready workforce. From self-paced online courses and immersive virtual reality simulations to hands-on workshops and technology transfer programs, our training ecosystem supports continuous professional development across every level of vaccine production.

Whether enhancing technical know-how, guiding regulatory navigation, or empowering regional trainers in developing countries, DCVMN is committed to equipping manufacturers with the tools and knowledge needed to meet today's challenges and tomorrow's demands in vaccine development and delivery.




WEBINARS & WORKSHOPS

In 2024, DCVMN International continued to collaborate with its sponsors and resource members to deliver insightful live presentations and hands-on training sessions through its regular Webinar Series. Following the 2023 Feedback Survey, webinars were extended to 1h30min and began incorporating Poll sessions, while maintaining the dedicated 20-minute Q&A for direct engagement with panelists. All webinars are hosted on Zoom, and their recordings are published on the DCVMN website [1] when authorized by the collaborators.

In the first three quarters of 2024, DCVMN hosted six webinars, reaching a total of 524 cumulative participations from professionals worldwide. A common thread across these sessions was the focus on process optimization along the vaccine production pipeline, covering areas such as technology transfer, local manufacturing, waste reduction, alternative production systems, and scale-up strategies. Remarkably, a historical record was achieved that year: the webinar on “Innovative Vaccine Technology Transfer and Local Manufacturing” reached the highest attendance in the past four years.

Number of connections, companies and countries at DCVMN webinars in 2024. Note that one connection may correspond to a group of persons attending. Chart graciously prepared by Ms. T. Lacerda.




[1] Slides and recordings of webinars are openly available on the DCVMN website (<https://dcvmn.org/webinar-materials/>) provided speakers had agreed.

E-LEARNING

The DCVMN E-learning platform offers meticulously-crafted courses by industry experts. Whether you are starting your career or aiming to enhance your skills, you will find valuable insights that will empower you in the vaccine field as the platform consolidates extensive technical and scientific knowledge. The e-learning platform offers a wide range of self-paced modules on various technical topics of common interest, allowing learners to enroll and complete courses at their own convenience. Since 2016, the platform has already served more than 7,840 enrolments comprising global vaccine workforce, educators, researchers, etc. Take control of your education and explore the enhanced features by visiting our E-Learning Platform.

DCVMN E-Learning platform currently hosts 26 self-paced modules designed to enhance professional skills, share best practices, and impart specific knowledge to vaccine manufacturers. Upon successful completion of a course, participants receive a Certificate of Achievement by scoring 80% or more in the final knowledge check at the end of the course. In 2024, the platform had 789 new enrollments to individual modules with 262 certificates awarded. E-courses are accessible at <https://moodle.dcvmn.net/>, upon registration.

Cumulative number of e-training enrollments to individual modules and cumulative number e-certificates achieved from 2017 to the end of 2024. Chart graciously prepared by Ms. M. Sharma.



DCVMN TECHNOLOGY TRANSFER TRAINING



The DCVMN Technology Transfer Training program is unique in its international scope, welcoming participants from across the Network. It provides essential professional exposure and expert guidance on technical mastery crucial for process optimization, development, and the transfer of vaccine knowledge. Mastering technology transfers is crucial for bridging the time and expense gap in vaccine manufacturing. By building local expertise and capacity, the program fosters a sustainable and self-reliant supply of global vaccines.

The curriculum of the training program delves into the intricacies of technology transfer, covering fundamental processes, operational aspects of vaccine development, and diverse tech transfer approaches and strategies. This hybrid training is divided into two distinct phases:

5 Weeks

Phase 1

The first phase of training features online sessions coupled with virtual trainers interaction setting the foundation by covering crucial aspects such as when and how to perform technology transfer, regulatory requirements, legal considerations, and potential pitfalls.

1 Week

Phase 2


This phase involves hands-on training. Participants gain immersive experience with cutting-edge technologies and have the opportunity to consult with subject-matter experts, providing a comprehensive understanding of practical applications.

In 2024, DCVMN, in collaboration with Hilleman Laboratories, successfully delivered the 4th edition of the DCVMN Technology Transfer Training Program. This edition brought together 15 participants from 12 DCVMN member companies across six countries in Asia, fostering a rich environment for knowledge exchange and regional collaboration.

Looking ahead to 2025, the upcoming 5th edition, will mark a key milestone with the second, hands-on phase of the training taking place in India for the very first time in collaboration with Panacea Biotec. This expansion underscores our commitment to regional capacity-building and ensuring more accessible, high-impact learning opportunities for our members in different environments.

VIRTUAL REALITY

Early in 2023, we proudly launched the [DCVMN VR Trainings](#), featuring three immersive modules tailored to provide hands-on experiences crucial for vaccine manufacturing, with a specific focus on laboratory and facility operations. DCVMN is the first global organization leveraging VR technology to deliver training in the vaccine manufacturing field. VR serves as the bridge between theoretical learning and practical training. It provides employees with a secure, simulated environment, allowing them to gain hands-on and environment experience even before entering the physical manufacturing facility. The modules are free to download for all on our website.




In 2024, we began the development of two new VR training modules, with expert contributions from our members. These modules are set to be finalized in 2025 and will further enhance our growing library of immersive, hands-on training experiences. To ensure broader accessibility and ease of use, all modules are now compatible with both Meta and Pico VR headsets—two of the leading devices in the market—making it easier for members to integrate VR into their workforce development strategies.

TRAINING DIRECTORY

Recognizing the critical role of continued professional development, DCVMN, in collaboration with NIIMBL, PATH, and Nexight Group, launched the Vaccines and Biologics Training Directory: a comprehensive, web-based tool designed to simplify access to high-quality training resources for vaccine manufacturers worldwide all in one place.

This free platform curates a wide range of professional development opportunities in biopharmaceutical and vaccine manufacturing, enabling users to easily identify the right programs to meet their specific needs. Whether seeking technical upskilling, regulatory training, or leadership development, the directory supports professionals at every level of the manufacturing ecosystem.



Expert Working Groups


DCVMN's expert Working Groups (WGs) are engines of collaboration, knowledge exchange, and problem-solving within the Network. Comprised of professionals from member manufacturing companies and guided by independent senior consultants, these groups focus on areas of shared strategic importance to the vaccine industry.

In 2024, six active Working Groups—Clinical Development & Medical Affairs (CDMA), Learning & Development (L&D), Healthy Industry Framework (HIF), Pharmacovigilance (PV), Regulatory Affairs (RA), and Supply Chain & Traceability (SC) — worked to advance technical capacity, align industry practices, and address systemic challenges faced by manufacturers in developing countries.

Each WG meets regularly to share best practices, identify industry-wide gaps, and co-develop solutions. Their work includes organizing technical meetings with global health institutions, designing and analyzing industry surveys, drafting white papers, and creating training and communication resources tailored to member needs. These efforts are currently supported through donor funding and contribute directly to strengthening the global vaccine manufacturing ecosystem.



The Expert Working Groups



Clinical Development & Medical Affairs

The Clinical and Medical Affairs Working Group (CDMA WG) identifies and assesses the members' capacity to develop and implement a benefit-risk approach for their Clinical and Medical activities. The purpose of the working group is to ensure that DCVMN member companies are equipped with state-of-the art methodology to provide vaccines according to international standards and guidelines, aligned with national and international regulatory requirements.



Learning & Development


Formed by experts across HR, Learning & Development, Quality, and Production departments, the L&D WG was established to address critical skill and knowledge gaps in the vaccine manufacturing workforce, particularly in light of PPPR priorities. By systematically identifying evolving training needs across technical and operational areas, the WG develops targeted initiatives including workshops, specialized training programs, and e-learning modules. These initiatives are designed to ensure that vaccine manufacturers are equipped with the talent and expertise required to respond rapidly and effectively to global health challenges.



Healthy Industry Framework


The Healthy Industry Framework Working Group is dedicated to developing structured tools and collaborative models that strengthen DCVMN members' value proposition and advocate for a sustainable and resilient vaccine industry, particularly in the Global South. The group focuses on empowering the Network by facilitating access to advanced vaccine technologies, securing funding for capacity upgrades and expansions, and building meaningful partnerships with key external stakeholders.

Pharmacovigilance




The vaccine pharmacovigilance (PV) working group identifies the needs to improve and strengthen pharmacovigilance systems for vaccine manufacturers in emerging countries so that DCVMN member companies are equipped with up-to date knowledge on how to improve global vaccine safety monitoring, operational pharmacovigilance capabilities and proactively identify and respond to potential safety issues, including resource implications, which are aligned with WHO and relevant national regulatory requirements.

Regulatory Affairs



The regulatory affairs working group shares the best practices in regulatory science and regulatory approaches. The group seeks to collaborate for the identification of regulatory challenges at both the pre-marketing and post-marketing stages in the vaccine life cycle. It explores potential opportunities for increased efficiency of regulatory processes worldwide, improvement of the vaccine registration procedures and processes (pre-registration stage) in countries, and to identify challenges and opportunities for the improvement of post-approval changes (PACs). The proposals from the group are shared widely with partners, such as WHO, and vaccine stakeholders who can encourage regulators in implementing some of the proposed changes for improvement.

Supply Chain & Traceability



The goal of the supply chain expert group is to share best practices and find common solutions for companies to increase the efficiency and effectiveness of their vaccine supply chain through innovation in the manufacturing and distribution stages. Presently, the group focuses on tracking vaccines (traceability), stockpiling and considering new packaging technologies. It develops position papers that can inform DCVMN members and the wider global immunity community on the specific actions DCVMN members could undertake to improve the vaccine supply chain, including net-zero approaches.

Healthy Industry Framework Working Group

Launched in early 2024, the Healthy Industry Framework (HIF) Working Group has brought together 9 dedicated members from Argentina, China, India, Indonesia, and South Africa. Since its inception, the group has hit the ground running, holding nine virtual meetings and a gathering during the 25th DCVMN AGM.

The WG is focused on empowering the Network by facilitating access to advanced vaccine technologies, securing funding for capacity upgrades and expansions, and forging meaningful partnerships with external stakeholders.

As they look to 2025, the group plans to implement a forward-thinking two pronged strategy—combining pre-competitive collaboration and competitive—to strengthen the Network's resilience and global standing. A big milestone for the upcoming year is the drafting of a cutting-edge platform designed to simplify funding access and foster knowledge-sharing on R&D and manufacturing best practices. This initiative aims to drive innovation, boost collaboration, and position the Network as a leader in global vaccine development.

Joint Working Group Workshop

In February 2024, DCVMN held a Joint Working Group Workshop in New Delhi, bringing together members from the Pharmacovigilance, Regulatory, and Clinical Development & Medical Affairs working groups. The workshop welcomed 22 participants from 7 member companies, joined by experts Katharina Hartmann, Pieter Neels, and Alexander Precioso from CEPI.

The workshop emphasized the importance of cross-functional integration throughout the vaccine lifecycle. Key discussions focused on strengthening pharmacovigilance, especially in addressing underreporting and improving real-time safety data collection in LMICs. Reflecting on lessons from COVID-19, the group proposed using Adaptive Clinical Trial designs to accelerate vaccine access. The CDMA WG will lead training on adaptive design, while the Joint WG will develop a regulatory position paper to support adoption.

Additional priorities identified included harmonizing pharmacopeias, streamlining post-approval changes, and tackling vaccine hesitancy through targeted training.

Learning & Development Working Group

In its inaugural year, the Learning and Development (L&D) Working Group has laid a strong foundation for workforce development within the vaccine manufacturing sector. Over the course of 2024, the group held 11 meetings, drawing on the diverse expertise of its members to address critical training needs across the DCVMN network.

To establish a clear baseline for its mission, the group conducted a comprehensive Training Needs Analysis survey, gathering nearly 250 responses from DCVMN member companies. The majority of respondents represented key operational areas, including Quality Assurance, Quality Control, and Manufacturing & Production, ensuring the results were both relevant and representative of industry priorities.

The survey findings highlighted several critical insights:

- **Multilingual Training Demand:** There is a clear need for multilingual training resources or translations to improve accessibility and inclusivity across diverse regions.
- **Internal Knowledge Sharing:** A strong willingness to train colleagues was evident, underscoring the potential for "train-the-trainer" programs. These initiatives would empower professionals to serve as in-house trainers, overcoming bandwidth challenges while fostering a culture of continuous learning.
- **Preferred Learning Methods:** Traditional classroom settings, interactive workshops, and practical, hands-on training emerged as the most favored learning formats, reflecting the desire for both foundational knowledge and experiential learning opportunities.



Guided by these insights, the L&D Working Group has prioritized three core training areas critical to enhancing workforce capabilities: Quality Culture, Leadership Development, and Communication Skills. Looking ahead, the group is planning to host specialized training workshops tailored to these focus areas, reflecting a shared commitment to equipping vaccine manufacturing professionals with the skills needed to drive innovation and uphold quality across the industry.

Launching the QbD and MSG Working Groups

In response to the need for skilled talent in vaccine manufacturing across LMICs, DCVMN launched an ambitious new initiative in 2024 to develop subject-matter expertise in Quality by Design (QbD) and Manufacturing Science Group (MSG) principles. Spearheaded by DCVMN CEO Rajinder Suri, this program aims to equip professionals to train manufacturing staff in emerging vaccine manufacturers, particularly in Africa. This ultimate goal aligns with the African Union's ambition to locally produce over 60% of the continent's vaccine needs by 2040.

With strategic support from the Gates Foundation and PATH, DCVMN collaborated with leading experts Jaap Koster (PCS, Netherlands), Dr. Baley Reeves (TEES, USA), and Amanda Zehnder (PATH) to shape the technical foundation of the initiative. Together we organized a dynamic three-day workshop held in Dubai from October 2–4, 2024.

The workshop featured:

- Expert-led training sessions on QbD and MSG methodologies tailored to vaccine manufacturing;
- Interactive discussions and peer learning, encouraging cross-organizational knowledge exchange;
- Strategic planning for building out formal training programs and delivery models.

This event marked the official launch of the QbD and MSG Working Groups, bringing together a core team of subject-matter experts from DCVMN member companies, along with the program's founding technical advisors. These working groups are now actively developing training programs from the ground up: designing curricula, creating learning materials, defining delivery formats, and preparing for rollout.

Set to be formalized as full DCVMN Working Groups in 2025, these teams represent a step in a transformative journey toward self-reliant vaccine production. By empowering the local workforce to train their colleagues, this initiative lays the groundwork for long-term sustainability and workforce resilience in LMICs.

Looking ahead, DCVMN is committed to expanding the reach of this program through collaboration with key global health partners, including WHO, CEPI, Africa CDC, and PAHO.



Regulatory Working Group

In 2024, through two major workshops, the group brought together regulatory specialists and industry experts to exchange insights, align strategies, and tackle shared challenges.

Brussels NGS Workshop

Held in June 2024, the three-day workshop in centered on the growing potential of Next-Generation Sequencing (NGS) in vaccine manufacturing and quality control. Participants explored the technology's promise in enhancing product safety, streamlining release timelines, and reducing costs. Key themes of the workshop included:

- **Transition to Non-Animal Testing:** Emphasizing cross-functional collaboration between R&D, QC, and regulatory affairs to build confidence in alternative approaches.
- **Validation of NGS:** Industry members and regulators shared best practices and considerations for validating NGS, aiming for broader acceptance and faster integration.
- **Regional Regulatory Alignment:** The group advanced work on key objectives such as promoting the adoption of WHO's TRS 993 guidelines in LATAM and pursuing pharmacopeial harmonization.

Geneva WHO Workshop

In October, the WG convened for a joint workshop with the WHO Department of Regulation and Prequalification. This collaborative platform provided a valuable opportunity to address both foundational and forward-looking topics in global vaccine regulation, including:

- **Post-Approval Guidance:** Review of updated WHO guidance on post-marketing changes, supporting continued alignment with evolving global standards.
- **Collaborative Registration Procedure (CRP):** Shared experiences on streamlining vaccine approval across countries to reduce delays in access.
- **Digital Innovation:** Introduction of a digital platform for managing vaccine life cycles, offering new tools for regulatory transparency.
- **Emergency Use Listing (EUL):** Interactive discussions focused on refining the EUL process to better serve public health needs in future emergencies.

Together, these workshops reinforced the Regulatory WG's core mission: to foster regulatory convergence, drive innovation, and support member manufacturers in navigating complex and shifting global requirements.



DCVMN at Global Meetings

Representation at High Level Forums and Meetings

In 2024, DCVMN took part in numerous high-level meetings, conferences, and working groups, demonstrating our unwavering dedication to advocate for our members and network on a global platform. Here is a glimpse of some key gatherings we attended:



ACT-Accelerator



Advancing Biomanufacturing Workforce Training for Global Health Equity



Bio-security, Bio-economy and Bio-safety Meeting



CEPI Joint Coordination Group (JCG)



Expert Committee on Biological Standardization (ECBS)



Facilitating Technology Transfer to Promote Local Manufacturing and Access to Vaccines, Medicines, and Health Technologies in Sub-Saharan Africa



Gavi Programme & Policy Committee



Global Forum for Vaccine Sovereignty and Innovation



Global Pandemic Preparedness Summit 2024



i-MCM-Net Partners Meeting



International Conference on Innovation, Intellectual Property, and Technology Transfer in Africa's Pharmaceutical Sector



Partnerships for African Vaccine Manufacturing (PAVM)



Regionalized Vaccine Manufacturing Collaborative



RVMC (Regional Vaccine Manufacturing Collaborative) Strategic Advisory Board



Strategic Advisory Group of Experts on Immunization (SAGE) Meetings



The Intergovernmental Negotiating Body (INB11)



UNICEF Vaccine Industry Consultation (VIC)



World Local Production Forum (WLPF)



World Vaccine Congress



2nd Edition of The Global Event on Harnessing Private Sector Engagement for Sustainable Vaccine and Pharmaceutical Manufacturing in Africa



5th Annual BactiVac Network Meeting



8th International Symposium on Immunobiologicals

Meetings DCVMN Members Were Invited To

Our esteemed members were invited to listen in and offer their invaluable expertise and guidance at various impactful meetings and projects. Some of these notable engagements include:



ACT-A meeting on Mpox



DCVMN-GAVI Consultation



Global Vaccine and Immunization Research Forum



High-level Meeting to Defeat Meningitis



PIP Framework Annual Partnership Contribution



UNICEF's Vaccine Industry Consultation on GHGE missions



Update on AVMA operationalization plan by GAVI



WHO Department of Regulation and Prequalification (RPQ) & DCVMN Meeting



WHO Implementation Workshop: Considerations in developing a regulatory framework for human cells and tissues and for advanced therapy medicinal products



WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC)

25th Annual General Meeting



8 Antigens are expected to achieve WHO PQ and enter the continental market between 2025 - 2030.

Drug substance	Drug product	Country of origin	Year of registration	Antigen demand (2025 - 2030)	% currently UNICEF approved
Artemisinin	Artemisinin	China	2025	100	100%
Artemisinin	Artemisinin	China	2025	100	100%
Artemisinin	Artemisinin	China	2025	100	100%
Artemisinin	Artemisinin	China	2025	100	100%
Artemisinin	Artemisinin	China	2025	100	100%
Artemisinin	Artemisinin	China	2025	100	100%
Artemisinin	Artemisinin	China	2025	100	100%
Artemisinin	Artemisinin	China	2025	100	100%
Artemisinin	Artemisinin	China	2025	100	100%
Artemisinin	Artemisinin	China	2025	100	100%

All 8 products have received market opportunities outside the UNICEF procurement channel.

25th Annual General Meeting

ACCELERATING SUSTAINABLE REGIONAL VACCINE
MANUFACTURING THROUGH GLOBAL PARTNERSHIPS



In October 2024, DCVMN marked a major milestone with the celebration of its 25th Annual General Meeting (AGM) in São Paulo, Brazil. Co-hosted by members Bio-Manguinhos/Fiocruz and Instituto Butantan, this special edition reflected how far the Network has come, from a modest gathering of manufacturers to a globally recognized event uniting vaccine producers, policymakers, international organizations, and global health leaders.

Held under the theme “Steering Change to Augment Vaccine Access & Environmental Sustainability,” the Silver Jubilee AGM blended reflection with ambition. Over three impactful days, more than 400 participants and 100 expert speakers engaged in rich discussions, forging new connections and reaffirming the urgency of global collaboration.

The opening ceremony featured distinguished guests including Ms. Regiane Cardoso de Paula, representing São Paulo’s Secretary of Health; Dr. Carlos Gadelha, Brazil’s Secretary of Science, Technology and Innovation; and India’s Honourable Ambassador to Brazil, Mr. Suresh Reddy, setting an inspiring tone for the days ahead.

Throughout the event, participants explored the evolving vaccine landscape examining advances in mRNA technology and AI, discussing lessons learned from recent pandemics, and addressing how the climate crisis intersects with global health. Sessions highlighted the need to tackle vaccine hesitancy, strengthen regulatory pathways, and need for long-term financing rooted in trust.

A defining feature of the 25th AGM was its spirit of collaboration and shared purpose. What began as a modest gathering of manufacturers 25 years ago has evolved into a flagship global event, a space where partnerships are forged, ideas are exchanged, and progress is accelerated.

Financial Statements

BALANCE SHEET AS AT 31 DECEMBER 2024

ASSETS		31.12.2024	31.12.2023
		USD	USD
Current assets			
Liquidities		1'149'072.13	686'607.63
Investments with a quoted market price		3'108'120.32	2'646'657.32
Membership fee to receive		72'000.00	52'000.00
Provision for loss on membership to receive		-20'000.00	-20'000.00
Advance deposit for expenses		5'000.00	5'000.00
Regus deposit		608.00	654.69
Prepaid expenses and accrued income		9'356.91	32'751.10
Total current assets		4'324'157.36	3'403'670.74
TOTAL ASSETS		4'324'157.36	3'403'670.74
LIABILITIES			
Short-term liabilities	Notes		
Payables		12'080.51	29'862.29
Donations carryover	3.1	422'320.78	104'948.88
Accrued expenses		49'839.27	42'805.34
Total short-term liabilities		484'240.56	177'616.51
Unrestricted reserves			
Capital		3'226'054.23	2'778'481.20
Net result for the year		613'862.57	447'573.03
Total unrestricted reserves		3'839'916.80	3'226'054.23
TOTAL LIABILITIES AND RESERVES		4'324'157.36	3'403'670.74

INCOME AND EXPENSES STATEMENT FOR THE YEAR ENDED 31 DECEMBER

		2024	2023
		USD	USD
Income	Notes		
Members contributions		920 000.00	920 000.00
Provision for loss on members contributions for previous year		-20 000.00	-20 000.00
Reversal provision for loss on members contributions for previous year		20 000.00	15 000.00
Loss on members contributions		-20 000.00	-21 000.00
Sponsors contributions		402 001.00	287 250.00
Restricted donations received		943 450.00	797 750.00
Donations carryover from previous year		104 948.88	82 251.16
Donations carryover to the next year	3.1	-422 320.78	-104 948.88
Annual meeting contribution participants		26 583.51	23 864.60
Total income before financial income		1 954 662.61	1 980 166.88
Total income		1 954 662.61	1 980 166.88
Operating expenses			
Training Initiative		-108 210.92	-301 969.38
VR Program		-10 466.33	-17 821.24
Workshops		-96 644.72	-39 923.14
Consultants TBD-Business Modeling		-50 000.00	-30 000.00
Knowledge exchange and databases initiative		-6 654.64	-9 790.37
Travel		-5 804.63	-5 307.47
Pharmacovigilance initiative		-52 592.38	-57 539.07
Regulatory Forum initiative		-81 943.21	-43 797.50
Best practice supply WG		-10 903.72	-3 687.31
Shipment		0.00	-1 100.10
Annual General Meeting		-154 505.22	-144 001.55
Total operating expenses		-577 725.77	-654 937.13
Staff Costs			
Salaries		-586 194.84	-611 478.49
Social contributions AVS/AI/APG/AC/PCFam		-5 877.18	-16 929.97
Social and accident insurances		-1 272.79	-3 473.79
LPP contribution		-3 619.31	-9 799.96
Total staff costs		-596 964.12	-641 682.21
Other operating expenses			
Office rental		-8 696.78	-8 481.82
Office supplies		-22 702.51	-29 543.86
Accounting services		-39 227.82	-28 716.16
Legal consulting		-18 501.18	-36 292.20
HR and payroll services		-18 878.94	-18 954.06
Other services		-50 027.65	-42 552.44
Trademark fee		-19 413.96	0.00
Membership fee and donation		-1 000.00	-26 000.00
Financial audit		-11 177.17	-12 960.49
Publications		0.00	-2 193.57
Management expenses		-55.38	-408.31
Travel expenses		-73 935.28	-98 849.36
Miscellaneous		0.00	-644.25
Total other operating expenses		-263 616.67	-305 596.52
EARNINGS BEFORE INTEREST AND TAXES		516 356.05	377 951.02
Financial income and expenses			
Interests paid		-0.28	-77.44
Gain on investments		160 266.23	127 283.57
Bank charges		-18 005.45	-15 488.51
Foreign exchange loss		-18 299.36	-18 875.09
Total financial income and expenses		123 961.14	92 842.53
EARNINGS BEFORE TAXES		640 317.19	470 793.55
Prior-period and extraordinary income and expenses			
Others income		1 444.95	509.091
Taxes on previous year		-934.06	-729.61
Total prior-period income and expenses		510.89	-220.52
RESULT BEFORE TAXES		640 828.08	470 573.03
Local taxes		-26 965.51	-23 000.00
NET RESULT FOR THE YEAR		613 862.57	447 573.03

Notes to the Financial Statements

1. Overview

Purpose of the association

DCVMN is a public health driven, international alliance of manufacturers, working to strengthen vaccine manufacturers through the provision of information and professional training programs, technology improvements, innovative vaccine research and development, encouraging technology transfer initiatives, and educating the public about the availability of safe, effective and affordable vaccines for all people.

2. Accounting principles applied in the preparation of the financial statements

These financial statements have been prepared on the basis of the following elements:

Foreign currency translation

Assets and liabilities in foreign currencies are translated into US Dollar at the exchange rate in effect at the balance sheet date. Transactions in foreign currencies are translated into US Dollar at the rate in effect at the average monthly rate.

Liquidity

Cash and cash equivalents are carried in the balance sheet at their nominal value.

Investments with a quoted market price

Investments with a quoted market price are valued at the market price.

Membership fee to receive

Members contributions to receive are carried at their nominal value. Charges are calculated for these assets on an individual basis.

Payables

Payables are recorded in the balance sheet at their nominal value on the basis of invoices corresponding to services made on the date of closing.

Recognition of revenues and expenses

Revenues are recorded on the principle of periodicity, i.e., when revenue-generating transactions or events occur rather than on the basis of cash flows. Expenses are recorded according to the principle of periodic delimitation, i.e. when the operations or events generating expenses occur and not according to cash flows.

3. Details, analyses and explanations to the financial statements

Number of full-time

The number of full-time employee equivalents did not exceed 10 on an annual average basis.

Pension liabilities

On 31 December 2024 the liability to the pension scheme amounted to USD 0.- (31 December 2023: USD 0.-).

Explanations of income and expenses statement

3.1 Donations carryover to the next year

The amount of USD 422'320.78 (PATH for USD 411'084.08 and PSPT for USD 11'236.70) was unused by 31st December 2024 and therefore deferred as carryover to be disbursed in 2025, with agreement of the donor. Carryover is the process by which unobligated funds remaining at the end of a budget period may be carried forward to the next budget period to cover allowable costs in that budget period. The carryover of funds enables grantees to use unexpended prior year grant funds in the next budget period.

3.2 Loss on members contributions

A provision on loss on members contributions for an amount of USD 20'000 has been booked for the year 2024.

4. General comments

1. DCVMN annual revenue from memberships and donations in 2024 increased by 13%, to USD 2'292'034.51 before carryover, and before the variation on the provision on members contributions, from USD 2'022'864.60, in 2023. This is mainly related to increase sponsors contributions and restricted donations received, as compared to 2023.

2. Membership status as of December 2023 indicated that there were 42 members, of which 16 were full members (with WHO PQed vaccines). In 2024 no member left the network and two members did not settle their membership contributions.

3. The Network's activities and interim financial statements (up to Q3/2024) were presented by the Treasurer, on behalf of the Board, to the General Assembly of members on 16th October 2024.

4. The Board of members proposed budget for 2025 approved by the members assembly is targeted at USD 1'463'000.- for DCVMN Office and USD 1'050'194.- for grants.- income and ca. USD 1'457'139.- for DCVMN Office and USD 1'050'194.- on grants for expenses, which includes carryover funds from donors.

5. The income budget for 2025, was based on the assumptions below:

a) a pledge of USD 1'050'194.-, allocated for training and related activities in 2025 (grants already signed in 2023).

b) the membership contributions expected to increase to USD 968'000 (USD 920'000 in 2024).- The funds received from members are dedicated to administrative operations including secretariat, rental, IT, supplies, communication and staff salaries.

c) continuous corporate sponsorship contributions estimated at ca. 350'000.- USD, for workshops and AGM.

Note that exchange rate volatility may influence the budget up/downwards.

6. All income and disbursements are handled exclusively by bank transfers, providing traceable, independent and accurate accounting records, complying with international accounting and business practices. All disbursements are subject to a two-signature system approval, prepared by the Secretariat and approved by the Treasurer, with two witnesses, an external comptroller and a DCVMN member. All disbursements correspond to bank transaction records and invoices corresponding to services. Accounts are available to corporate members, nominated by the Board of members, as well as by donors and local authorities, for financial review and assessment.

ANNEX

1. DCVMN Board Structure 2023-26


The DCVMN Board is composed of seven elected members with skills and experiences to provide governance oversight to the DCVMN secretariat, through the Chief Executive Officer, Mr. Rajinder Kumar Suri. All Board members act on a voluntary, non-remunerated basis. In 2024, the DCVMN Board held 7 formal governance meetings, both in-person and virtually, on the following dates: 7 February, 23 March, 9 May, 31 July, 11 September, 15 October, 16 December, with a pre-set agenda and relevant documents circulated in advance to facilitate informed decisions. Minutes to the formal virtual meetings are accessible to all members to consult at <https://dcvmn.org/board-meeting-minutes/>.

Role	Name	Affiliation	Attendance out of 7 virtual meetings in 2024
Chair	Adriansjah Azhari	BioFarma	7
Co-chair	Tiago Rocca	Butantan	7
Member	Sunil Gairola	Serum Institute of India	6
Member	Rachel Park	EuBiologics	6
Member	Andrew Wong	Walwax	7
Member	Mauricio Zuma Medeiros	Bio-Manguinhos	6
Member	Venkatraman Sivaramakrishnan	Bharat Biotech	6
Treasurer (non-voting)	Fernando Lobos	Sinergium Biotech	7
CEO (non-voting)	Rajinder Kumar Suri	DCVMN International	7

2. Donors Advisory Committee

The Donors Advisory Committee (DAC) advises DCVMN on donor funded activities, and has no executive role. As a strictly advisory, non-governing body, the DAC does not have either decision-making authority or fiduciary responsibilities. It is composed by two DCVMN members and six external advisers from: Gates Foundation, Imperial College, International Finance Corporation and National Institute for Innovation in Manufacturing Biopharmaceuticals, PATH, and U.S. International Development Finance Corporation who are supporting and guiding the Network on principles, technical and scientific activities for member manufacturers, e.g. training programs. Members are appointed by the Executive Committee according to advice and support requirements. Appointment duration is dependent on the Advisory Committee needs and individual availability. The Advisory Committee held 2 virtual meetings in 2024 (March 1st and July 10th).

3. DCVMN Secretariat Structure 2024



Acknowledgements

We are grateful for our corporate sponsors for helping foster manufacturing excellence for the benefit of all people, facilitating knowledge sharing and intensifying training opportunities for a skilled industry workforce in developing countries.



We thank PATH for their grant to DCVMN International, continuing to support our professional training programs. We also thank Bio-Manguinhos / Fiocruz and Instituto Butantan for co-hosting the 25th DCVMN Annual General Meeting.





Important Note: The views expressed in this publication do not necessarily represent decisions or policies of any institutions mentioned or with which the Network is associated.




DCVMN INTERNATIONAL


Developing Countries Vaccine
Manufacturers Network International

 +41 22 595 1393

 Route de Crassier, 7 CH-1262 Nyon, Switzerland

 info@dcmn.net

 www.dcmn.org

 linkedin.com/company/dcmn